Turn Your Science Into a Venture That Gets Funded

If you are reading this, you have almost certainly already done the hardest part. You have built something scientifically real — a platform, a mechanism, a data package that represents years of rigorous work. And you are now facing the part that no PhD program, postdoc, or research leadership role prepared you for: turning that science into a fundable, defensible, scalable venture in one of the most capital-intensive and legally complex industries on earth.

I built BioVenture Executive because I kept seeing the same failure mode repeat itself. Brilliant scientists with genuinely differentiated science losing deals, equity, and momentum — not because their biology was wrong, but because they walked into term sheet negotiations without understanding liquidation preferences, signed licensing agreements that quietly handed control of their IP to a university, or pitched investors with financial projections that revealed they had never modeled a burn rate against a clinical milestone schedule. These are not intelligence failures. They are information gaps. And they are completely closable.

Every module in this program is built around the decisions you will actually face. Not abstract theory — real deal structures, real IP landscaping methodology, real VC fund mechanics, real CDMO selection frameworks. When we work through venture formation, you are making governance and entity structure decisions that will affect your cap table five rounds from now. When we build your IP strategy, you are doing the freedom-to-operate thinking that your patent counsel will eventually bill you hundreds of dollars an hour to explain. When we construct your financing plan, you are building the exact multi-stage narrative — grants to angel to Series A to potential public offering — that a sophisticated life sciences investor expects to see sequenced coherently before they engage seriously.

I also want to be direct about the executive leadership component, because it is where many scientist-founders most underestimate the work. Investors do not just fund science. They fund teams, governance structures, and organizational readiness. The final arc of this program — building your executive dashboard, your KPI framework, and your organizational readiness assessment — is not a soft-skills add-on. It is the infrastructure that transforms a promising asset into an institution that can attract, retain, and be trusted with serious capital.

The capstone is the proof. By the time you complete the Integrated Biotechnology Venture Portfolio, you will have a real, investor-facing pitch package — commercialization roadmap, IP strategy, financing plan, regulatory narrative, partnership framework, and governance dashboard — that reflects the full strategic architecture of your venture. That is what this program is designed to produce.

If you are ready to develop the commercial and executive fluency that matches the scientific credibility you have already earned, I am ready to work with you. The curriculum is rigorous by design, because the industry you are entering is unforgiving of gaps. Let's close them.